Senti Biosciences (SNTI) Competitors $2.20 -0.01 (-0.45%) Closing price 04:00 PM EasternExtended Trading$2.20 0.00 (0.00%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. CGC, PRQR, NBTX, YMAB, IMAB, CRDF, INBX, MDWD, SOPH, and MNPRShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Canopy Growth (CGC), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), Y-mAbs Therapeutics (YMAB), I-Mab (IMAB), Cardiff Oncology (CRDF), Inhibrx Biosciences (INBX), MediWound (MDWD), SOPHiA GENETICS (SOPH), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Its Competitors Canopy Growth ProQR Therapeutics Nanobiotix Y-mAbs Therapeutics I-Mab Cardiff Oncology Inhibrx Biosciences MediWound SOPHiA GENETICS Monopar Therapeutics Canopy Growth (NASDAQ:CGC) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has more risk and volatility, CGC or SNTI? Canopy Growth has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Is CGC or SNTI more profitable? Senti Biosciences has a net margin of 0.00% compared to Canopy Growth's net margin of -195.76%. Canopy Growth's return on equity of -88.54% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Canopy Growth-195.76% -88.54% -40.78% Senti Biosciences N/A -177.24%-67.38% Do analysts prefer CGC or SNTI? Canopy Growth presently has a consensus price target of $2.00, indicating a potential upside of 62.60%. Senti Biosciences has a consensus price target of $8.50, indicating a potential upside of 286.36%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, CGC or SNTI? Senti Biosciences has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanopy Growth$225.65M1.00-$429.86M-$4.04-0.30Senti Biosciences$2.56M22.41-$52.79M-$10.84-0.20 Do institutionals and insiders have more ownership in CGC or SNTI? 3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 1.3% of Canopy Growth shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor CGC or SNTI? In the previous week, Canopy Growth and Canopy Growth both had 3 articles in the media. Canopy Growth's average media sentiment score of 0.99 beat Senti Biosciences' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySenti Biosciences beats Canopy Growth on 10 of the 15 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.64M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-0.2020.8027.0020.10Price / Sales22.41286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book0.417.487.985.56Net Income-$52.79M-$55.04M$3.16B$248.40M7 Day Performance0.46%5.44%3.69%6.04%1 Month Performance-42.71%2.38%2.91%7.69%1 Year Performance-32.68%5.53%34.30%20.97% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences2.092 of 5 stars$2.20-0.5%$8.50+286.4%-33.9%$57.64M$2.56M-0.204CGCCanopy Growth2.8147 of 5 stars$1.22flat$2.00+63.9%-81.1%$224.32M$225.65M-0.303,150News CoveragePRQRProQR Therapeutics2.1054 of 5 stars$2.04flat$8.00+292.2%+25.9%$214.63M$20.46M-5.83180News CoverageNBTXNanobiotix1.6787 of 5 stars$4.73+4.4%$8.00+69.1%-13.1%$213.34M$39.18M0.00100News CoverageGap UpYMABY-mAbs Therapeutics3.2686 of 5 stars$4.51-4.0%$15.60+245.9%-63.0%$212.84M$88.66M-7.05150IMABI-Mab2.8748 of 5 stars$2.42-5.8%$6.00+147.9%+30.6%$209.87M$3.89M0.00380Gap UpCRDFCardiff Oncology1.6894 of 5 stars$3.15flat$9.88+213.5%+65.2%$209.56M$680K-3.4220Analyst ForecastINBXInhibrx Biosciences0.9825 of 5 stars$14.27-1.1%N/A+42.4%$208.89M$200K0.12166MDWDMediWound1.619 of 5 stars$19.37+0.6%$31.80+64.2%-1.7%$208.16M$20.22M-9.2780News CoverageSOPHSOPHiA GENETICS2.3357 of 5 stars$3.10+0.3%$7.00+125.8%-29.3%$206.06M$65.17M-3.10520News CoverageMNPRMonopar Therapeutics2.9043 of 5 stars$35.78+6.5%$56.50+57.9%+933.2%$205.47MN/A-10.2810News CoverageAnalyst Forecast Related Companies and Tools Related Companies Canopy Growth Alternatives ProQR Therapeutics Alternatives Nanobiotix Alternatives Y-mAbs Therapeutics Alternatives I-Mab Alternatives Cardiff Oncology Alternatives Inhibrx Biosciences Alternatives MediWound Alternatives SOPHiA GENETICS Alternatives Monopar Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNTI Stock Alerts